蒙特卡洛模拟评价万古霉素治疗金黄色葡萄球菌和表皮葡萄球菌引起血流感染的给药方案
2023-03-13金丹婷杨晋茆海丰喻玮嵇金如应超群刘志盈邹秀珍肖永红
金丹婷 杨晋 茆海丰 喻玮 嵇金如 应超群 刘志盈 邹秀珍 肖永红



摘要:目的 利用蒙特卡洛模擬评价万古霉素治疗金黄色葡萄球菌和表皮葡萄球菌引起血流感染的合理性。方法 由全国血流感染细菌耐药监测联盟(BRICS)收集全血标本中分离的1438株金黄色葡萄球菌和409株表皮葡萄球菌,采用微量肉汤稀释法对分离的菌株进行最低抑菌浓度(minimum inhibitory concentration,MIC)的测定。万古霉素4种给药方案分别为500mg q6 h、1000 mg q12 h、1500 mg q12 h和2000 mg q12 h。通过蒙特卡洛模拟10000例次后,获得4种给药方案的fAUC/MIC达标概率 (probability of target attainment,PTA)和累计反应分数(cumulative fraction of response,CFR)。CFR≥90%时的给药方案是经验性用药的最佳选择。结果 当对葡萄球菌MIC≤0.5 mg/L时,万古霉素4种给药方案fAUC/MIC均可达到满意的抗菌活性(PTA=100%),当MIC=1 mg/L时,1500 mg q12 h和2000 mg q12 h两种给药方案可达到目标PTA。万古霉素给药剂量500 mg q6 h、1000 mg q12 h、
1500 mg q12 h、2000 mg q12 h对金黄色葡萄球菌的fAUC/MIC CFR分别为83%、83%、87%和98%;对应表皮葡萄球菌的CFR分别为53%、53%、59%和92%。结论 万古霉素用于因金黄色葡萄球菌和表皮葡萄球菌引起的血流感染时,应根据MIC值的不同而选择不同的给药剂量进行治疗,经验性选择万古霉素进行抗感染治疗时,给药剂量需达到2000 mg q12 h方能达到较好的抗菌效果。
关键词:蒙特卡洛模拟;万古霉素;累计反应分数
中图分类号:R978.1文献标志码:A
Monte Carlo simulation to evaluate vancomycin dosing regimens in the
treatment of bloodstream infection caused by Staphylococcus aureus
and Staphylococcus epidermidis
Jin Danting1, Yang Jin1, Mao Haifeng1, Yu Wei2, Ji Jinru2, Ying Chaoqun2, Liu Zhiying2,
Zou Xiuzhen1, and Xiao Yonghong2
(1 The First Affiliated Hospital of Kangda College, Nanjing Medical University The First People's Hospital of Lianyungang, Lianyungang 222002; 2 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,
The First Affiliated Hospital, Zhejiang University, Hangzhou 310003)
Abstract Objective To evaluate the appropriateness of vancomycin regimens in the treatment of bloodstream infection caused by Staphylococcus aureus and Staphylococcus epidermidis by Monte Carlo simulation(MCS). Method 1,438 strains of S. aureus and 409 strains of S. epidermidis isolated from blood samples were collected in the Blood Bacterial Resistant Investigation Collaborative System (BRICS) were examined for the minimum inhibitory concentration(MIC) of vancomycin with microbroth dilution method. The four regimens of vancomycin (500 mg q6 h, 1000 mg q12 h, 1500 mg q12 h and 2000 mg q12 h) were evaluated with MCS of 10,000 simulations, the probability of target attainment (PTA) and cumulative fraction of response (CFR) of fAUC/MIC of the regimens were obtained. CFR > 90% is the best choice for empiric administration. Results All the four vancomycin regimes could achieve satisfactory antibacterial PK/PD target (PTA=100%) when MIC ≤0.5 mg/L, and 1500 mg q12 h and 2000 mg q12 h
could achieve satisfactory targets when MIC=1 mg/L. The CFR against S. aureus after 500 mg q6 h, 1000 mg q12 h, 1500 mg q12 h and 2000 mg q12 h administration were 83%, 83%, 87% and 98%, respectively; The CFR against
S. epidermidis were 53%, 53%, 59% and 92%, respectively. Conclusion Treatment of bloodstream infections caused by S. aureus and S. epidermidis with vancomycin should be used in regimen referring to different MIC. Empiric therapy with vancomycin should be in the regimen of 2000 mg q12 h.
Key words Monte Carlo simulation; Vancomycin; Cumulative fraction of response
万古霉素(vancomycin, VAN)目前主要用于治疗耐甲氧西林的葡萄球菌属、青霉素非敏感的肺炎链球菌等引起的呼吸系统感染、中枢神经系统感染以及血流感染等[1]。作为革兰阳性球菌重症感染的一线治疗药物,万古霉素具有治疗窗口窄、个体间差异较大等特点[2-5]。随着临床广泛使用,虽然我国尚无万古霉素耐药葡萄球菌,但细菌对万古霉素敏感性发生改变 ,既往所设定的给药方式是否符合现阶段临床实际需要进一步研究。本……
